Afatinib is an FDA-approved irreversible blocker of the tyrosine kinase of the EGFR for treating advanced or metastatic non-small-cell lung cancer (NSCLC) (Wecker and Waller, 2018). Here, EGFR is linked to non-small cell lung carcinoma.